Zymeworks (ZYME) Interest & Investment Income (2023 - 2026)
Zymeworks (ZYME) posted Interest & Investment Income of -$486000.0 for Q1 2026, down 1575.86% sequentially from -$29000.0 in Q4 2025, and down 189.01% YoY from $546000.0 in Q1 2025.
Zymeworks (ZYME) Interest & Investment Income (2023 - 2026) Analysis & Trends
Zymeworks has reported Interest & Investment Income for 4 years, with the latest figure at -$486000.0 in Q1 2026.
- Quarterly Interest & Investment Income fell 189.01% year-over-year to -$486000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$159000.0 (down 112.06% YoY) and the FY2025 annual result came in at $873000.0, up 350.14% from the prior year.
- Interest & Investment Income fell to -$486000.0 in Q1 2026 per ZYME's latest filing, from -$29000.0 in the prior quarter.
- Over five years, Interest & Investment Income peaked at $1.9 million in Q3 2024 and troughed at -$1.9 million in Q2 2023.
- A 4-year average of $7230.8 and a median of -$29000.0 in 2025 frame the typical range for Interest & Investment Income.
- The widest YoY moves for Interest & Investment Income: up 492.78% in 2024, down 255.69% in 2024.
- Over 4 years, Interest & Investment Income stood at $1.7 million in 2023, then tumbled by 156.22% to -$953000.0 in 2024, then surged by 96.96% to -$29000.0 in 2025, then sank by 1575.86% to -$486000.0 in 2026.
- According to Business Quant data, Interest & Investment Income over the past three periods registered -$486000.0, -$29000.0, and $290000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 48.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 35.58 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 27.90 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 5.13 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 28.14 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Zymeworks | 1.79 Bn | 1.52 Bn | - | -129,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -129,000.00 |
| Mar 31, 2026 | -486,000.00 |
| Dec 31, 2025 | -29,000.00 |
| Sep 30, 2025 | 290,000.00 |
| Jun 30, 2025 | 66,000.00 |
| Mar 31, 2025 | 546,000.00 |
| Dec 31, 2024 | -953,000.00 |
| Sep 30, 2024 | 1.91 Mn |
| Jun 30, 2024 | -180,000.00 |
| Mar 31, 2024 | -1.12 Mn |
| Dec 31, 2023 | 1.70 Mn |
| Sep 30, 2023 | -485,000.00 |
| Jun 30, 2023 | -1.87 Mn |
| Mar 31, 2023 | 720,000.00 |